tion of TNF-a bioactivity is of therapeutic potential for treatment groups: saline, SB202190, LPS, LPS plus LPS-induced myocardial dysfunction. However, the cel-SB202190 and LPS plus etanercept. Mice were treated lular and molecular mechanism by which LPSs induce intraperitoneally (i.p.) with a p38 MAPK inhibitor TNF-a expression in myocardium remains largely un-SB202190 (2 mg / kg) or saline, 30 min later, followed by known.
LPS (10 mg / kg, n59 mice / group). Seven mice were The mammalian p38 mitogen-activated protein kinase pretreated with etanercept (2 mg / kg, i.p.), a TNF-a (MAPK) was originally identified in murine pre-B lymblocking protein containing the extracellular ligand-bindphocytes transfected with the LPS-complex receptor CD14
ing portion of the p75 TNF-a receptor (recombinant and in murine macrophages where it was activated in human TNFR:Fc, Immunex, Seattle, WA, USA) [20] and response to LPS [11] . Since then, p38 MAPK has been LPS (10 mg / kg, i.p.) was given 1 h later. Mice treated found to influence a multitude of cellular events, such as with saline (n57) or SB202190 alone (n55) served as cell growth and death, cell proliferation, differentiation and respective controls. Left ventricular (LV) function was inflammation [12] . In the heart, p38 MAPK is activated in assessed 2 h after LPS or saline treatment during anescardiac myocytes by cellular stress and hypertrophic thesia. At the end of hemodynamic measurement, mice stimuli, and is implicated in hypertrophy, survival and were euthanized, and the LV myocardium and plasma were apoptosis of cardiomyocytes [13, 14] . In response to LPS, collected and stored at 270 8C. For time course experiactivation of p38 MAPK has been demonstrated to be an ments, mice were treated with LPS (10 mg / kg, i.p.) and essential signaling mechanism governing the regulation of sacrificed at 15 min, 30 min, 1, 2 and 4 h (n55 for each TNF-a expression in the neutrophils and macrophages time point). The LV myocardium and plasma were col- [15, 16] . However, significant differences appear to exist lected for measurements of TNF-a expression and p38 between different cell types with respect to the role of p38 MAPK phosphorylation. MAPK in TNF-a synthesis. For example, in the mast cell, Survival was monitored in the following three groups of production of TNF-a is not linked to activation of p38 mice: (1) Saline pretreatment followed by LPS (20 mg / kg, MAPK [17, 18] . These differences indicate that the role of i.p., n517); (2) SB202190 pretreatment (2 mg / kg, i.p.) p38 MAPK activation in TNF-a synthesis is likely cell followed by LPS (20 mg / kg, i.p., n517); (3) etanercept type specific. In this regard, we have recently demonstrated pretreatment (2 mg / kg, i.p.) followed by LPS (20 mg / kg, that LPS rapidly increased phosphorylation of p38 MAPK i.p., n515). LPS was administered 30 min after saline and in cultured neonatal mouse cardiomyocytes and inhibition SB202190 treatment, and 1 h after etanercept administraof p38 MAPK activation abrogated LPS-induced TNF-a tion. expression, suggesting an important role of p38 MAPK signaling in LPS-induced TNF-a production in cardiomyocytes in vitro [19] . However, the role of p38 2 .3. Hemodynamic measurements MAPK in myocardial dysfunction during endotoxemia in vivo remains to be determined. The aim of the present Mice were anesthetized with intraperitoneal injections of study was to investigate the contribution of p38 MAPK to ketamine (50 mg / kg) and xylazine (15 mg / kg). Measuremyocardial TNF-a expression, cardiac function and surments of LV pressure were obtained using a tip-transducer vival during acute endotoxemia in mice by pharmacocatheter (1.4F, Millar Instruments, TX, USA) as we logical inhibition of p38 MAPK activation.
previously described [21] . Briefly, the catheter was calibrated at the beginning of each experiment. Consistent with what we showed in cultured neonatal TNF-a protein levels in the LV myocardium and plasma mouse cardiomyocytes [19] , LPS treatment in vivo inwere determined using a mouse TNF-a enzyme-linked duced an increase in phosphorylation of p38 MAPK in the immunosorbent assay (ELISA) kit (ALPCO Diagnostics, adult mouse myocardium. Fig. 1 illustrates the time course USA) according to the manufacturer's instructions. The LV of p38 MAPK phosphorylation in the LV myocardium after tissues were homogenized in phosphate-buffered saline an intraperitoneal LPS administration. LPS rapidly in-(PBS). After centrifugation, the supernatant was collected creased phosphorylation of p38 MAPK and reached the for protein concentrations. TNF-a measurements were maximum around 15-30 min and returned to basal levels standardized with sample proteins and the plasma volume.
after 4 h. TNF-a mRNA expression in response to LPS started within 15 min and reached the maximal level around 1 h in the LV myocardium (Fig. 2) . The sequential 2 .6. Immunohistochemistry activation of p38 MAPK and TNF-a expression after LPS treatment suggests a causal relationship between LPSSections of formalin-fixed and paraffin-embedded induced p38 MAPK activation and TNF-a expression in myocardial tissue were analyzed by an indirect immunothe mouse myocardium in vivo. In order to clarify that peroxidase technique [22] . Briefly, 5-mm sections were increased phosphorylation of p38 MAPK and induction of incubated sequentially with primary antibody overnight at TNF-a expression in the myocardium did not result from 4 8C, and then with peroxidase-conjugated donkey antithe circulating TNF-a after LPS administration, we meagoat IgG antibody. Each incubation was followed by three sured TNF-a levels in the plasma. After LPS treatment, washes with PBS. The reaction was developed with TNF-a protein was not detected in the plasma at 15 min, diaminobenzidine and H O . The reaction was terminated 2 2 but it was dramatically increased at 30 min and reached the by washing with PBS. Sections were counterstained with hematoxylin, dehydrated and mounted by routine methods. Goat polyclonal antibody (IgG) specific for TNF-a was purchased from Santa Cruz (USA).
.7. Analysis of p38 MAPK phosphorylation
Assessment of the phosphorylation status of p38 MAPK in the LV myocardium was accomplished by Western blotting [19] . Briefly, aliquots containing 30 mg of protein were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using 12% gels, followed by electrotransfer to ECL membranes. Blots were probed with antibodies against p38 MAPK / phospho-p38 MAPK (New England Biolabs, 1 / 1000), followed by incubation with horseradish peroxidase-conjugated secondary antibody (Bio-Rad). Detection was performed using an ECL chemiluminescence detection method. Signals were determined by densitometry. Levels of phosphorylated p38 MAPK to total p38 MAPK were presented. TNF-a expression in the myocardium were stimulated secondary to the circulating TNF-a induced by LPS administration.
.8. Statistical analysis

.2. Effect of p38 MAPK inhibitor on myocardial TNFa expression stimulated by LPS
We have recently demonstrated that p38 MAPK activation is required for LPS-induced TNF-a expression in cultured neonatal mouse cardiomyocytes [19] . In order to determine whether this is also the case in the myocardium in vivo, the effect of p38 MAPK inhibition on LPSinduced TNF-a expression was assessed in the whole animal model. LPS treatment for 2 h significantly increased TNF-a protein levels in the myocardium compared to sham (P,0.01). Pre-treatment of a selective p38 MAPK inhibitor, SB202190 (2 mg / kg, i.p.) for 30 min significantly decreased TNF-a mRNA (P,0.05, n55) and in plasma 2 h after LPS stimulation. Plasma levels of TNF-a were not detectable in saline and SB202190 groups (Fig. 5) . Pre-treatment of SB202190 (2 mg / kg) for 30 min maximum at 2 h (Fig. 3) . The result indicates that significantly decreased LPS-induced TNF-a protein levels increased phosphorylation and induction of TNF-a in the (P,0.05, n55) in plasma (Fig. 5) . These data suggest p38 myocardium preceded the appearance of circulating TNF-a MAPK activation also played an important role in moduin response to LPS. This excludes such possibility that lating the circulating TNF-a stimulated by LPS in mice. increased phosphorylation of p38 MAPK and induction of
.3. Localization of TNF-a expression in the myocardium
In order to localize the TNF-a expression in the myocardium, immunohistological staining of myocardial tissues was carried out using a TNF-a specific antibody. As shown in Fig. 6 , no positive signal was found in the myocardium from the sham animal (Fig. 6A) . Upon LPS stimulation for 2 h, almost all of the cardiomyocytes were stained positive for TNF-a in the myocardium. The positive signals were localized in the cytoplasm of cardiomyocytes (Fig. 6B) . Pre-treatment with SB202190 for 30 min decreased TNF-a staining in the myocardium induced by LPS (Fig. 6C) . The results further confirmed that cardiomyocytes were the major source of TNF-a production in the myocardium and blocking p38 MAPK activation inhibited TNF-a expression in response to LPS.
Mice were treated with LPS (10 mg / kg body weight, i.p.) for 15, 30 min, and 1, 2 and 4 h, respectively. Blood was collected and plasma was obtained by centrifugation. TNF-a protein was measured by ELISA.
.4. Hemodynamic changes
TNF-a protein was not detectable in plasma at 15 min, but it was dramatically increased at 30 min and reached the maximum at 2 h after LPS treatment. Data are mean6S.D. n55 per group.
In response to LPS (10 mg / kg, i.p.), mean arterial Fig. 5 . Reduction of LPS-induced TNF-a production in plasma by inhibition of p38 MAPK. The plasma was collected 2 h after saline, SB202190 or LPS treatment and TNF-a concentrations were determined by ELISA. Plasma TNF-a levels in sham and SB202190 groups were undetectable. Pre-treatment with SB202190 for 30 min significantly decreased TNF-a production in plasma in response to LPS (* P,0.05). TNF-a levels were expressed as ng / ml plasma. Data are mean6S.D. n55 per group.
.5. Survival
LPS-treated (20 mg / kg, i.p.) mice showed signs of treated mice died at 72 h. Therefore, pretreatment with p38 MAPK inhibitor and TNF-a antagonist significantly improved survival during acute endotoxemia in mice (P, pressure (MAP) was significantly decreased, whereas heart 0.01). rate was significantly increased (P,0.05, in an immediate and transient increase in p38 MAPK alone did not have any effects on any of the parameters. activation, which was followed by TNF-a production in Pretreatment of SB202190 (2 mg / kg, i.p.) induced a the myocardium. Inhibition of p38 MAPK activation significant increase of LV 1dP/dt and 2dP/dt (P, decreased myocardial TNF-a expression and improved max min 0.05) without affecting MAP, HR or LVSP in endotoxemic cardiac function and survival during endotoxemia in mice. mice. Furthermore, pretreatment with etanercept (2 mg / kg, Our data support the notion that activation of p38 MAPK i.p.) significantly increased LVSP, LV 1dP/dt and plays an important role in TNF-a expression in the max 2dP/dt in LPS-treated mice (Table 1 , P,0.05). These myocardium and myocardial depression in endotoxemia.
min results demonstrated that inhibition of p38 MAPK and Myocardial dysfunction is a common clinical mani-TNF-a ameliorated cardiac dysfunction induced by LPS in festation in sepsis and septic shock [23] . Although the mice.
exact cause of myocardial depression during sepsis and septic shock is not fully understood, production of cytokines such as TNF-a and interleukin-1b is certainly involved [24] . Whereas macrophages and monocytes are considered to be a predominant source of circulating TNFa in response to LPS stimulation [25] , it is now clear that cardiomyocytes are the major local source of TNF-a in the myocardium [6] [7] [8] . However, the mechanism by which LPS stimulates TNF-a expression in cardiomyocytes has not been fully defined. We recently demonstrated that activation of p38 MAPK plays an important role in LPSinduced TNF-a expression in cultured neonatal mouse cardiomyocytes [19] . In the present study, treatment with LPS increased p38 MAPK phosphorylation which preceded myocardial TNF-a expression. Pre-treatment with SB202190, a selective inhibitor of p38 MAPK, markedly inhibited both TNF-a mRNA and protein expression in the myocardium induced by LPS. Furthermore, immunohistological staining showed that TNF-a expression was localized in the cytoplasm of cardiomyocytes and SB202190 administration decreased TNF-a staining signals in the myocardium from LPS-treated mice. Our data clearly indicate that p38 MAPK signaling is an important pathway leading to TNF-a expression in response to LPS stimulation in the myocardium in vivo. Accumulating evidence suggest that p38 MAPK plays an important role in myocardial dysfunction in various animal models. For example, in a mouse model of ischemia and reperfusion, p38 MAPK was activated in the heart and disruption of a single copy of the p38a MAPK gene decreased infarct size [26] . In a rat model of cardiac hypertrophy and dysfunction, hypertensive end-organ damage and premature mortality were shown to be p38 MAPK dependent [27] . Furthermore, transgenic mice with targeted activation of p38 MAPK in ventricular cardiomyocytes showed both systolic contractile depression and impaired diastolic function of the heart [28]. However, it remains unknown whether p38 MAPK has any effect on myocardial dysfunction during sepsis. In the present study, we demonstrated for the first time that LPS treatment resulted in a marked activation of p38 MAPK in the myocardium and significant decreases in both systolic and diastolic function. Furthermore, treatment with SB202190, a highly specific p38 MAPK inhibitor, ameliorated myocardial dysfunction and improved survival. These results suggest that activation of p38 MAPK contributes to myocardial dysfunction and high mortality during endotoxemia in mice. [7, 10] . In the present study we decreased myocardial TNF-a expression and improved myocardial function during endotoxemia. In order to contribute to the improved survival in the endotoxemic demonstrate the specific role of TNF-a in endotoxemia, mice. The nature of these effects and their relationship to etanercept-a fusion protein that blocks TNF-a was the cardiac effects of SB202190 and etanercept remain to utilized. Etanercept also improved cardiac function and be investigated. survival in endotoxemic mice. Our results suggest that In summary, we demonstrated that LPS treatment reattenuation of TNF-a expression represents an important sulted in significant activation of p38 MAPK in the mechanism by which inhibition of p38 MAPK improves myocardium. We showed for the first time that activation myocardial function and survival in endotoxemia. Activaof p38 MAPK plays an important role in the signal tion of p38 MAPK has also been shown to induce myocyte pathway leading to myocardial TNF-a expression in apoptosis and increase the expression of adhesion moleresponse to LPS in vivo. Furthermore, inhibition of p38 cules during myocardial ischemia and reperfusion [30, 31] , MAPK and TNF-a significantly improved myocardial 21 and decrease myofilament response to Ca in cultured function and survival during endotoxemia. Thus, p38 adult rat cardiomyocytes [32] . Whether these effects of p38 MAPK activation represents an important mechanism MAPK contribute to myocardial dysfunction in endotoxleading to myocardial TNF-a production and cardiac emia require further investigation. In the present study, dysfunction during acute endotoxemia. Our study suggests inhibition of TNF-a by SB202190 or etanercept increased that p38 MAPK is a therapeutic target of endotoxemia. LV contractility and survival suggests the contribution from improvement of cardiac function. It is possible that the extra-cardiac effects of SB202190 and etanercept may also
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